Our Company
About Curacell
Curacell is a European cell therapy company developing a Tumor Infiltrating Lymphocytes (TIL) based product for the treatment of cancer.
Founded on decades-long TIL research in Sweden and leading clinical expertise in Germany, we aim at delivering durable TIL treatments to patients with solid tumor cancers.
Large impact potential for oncology patients worldwide
Every cancer is different. Even if the same organ is affected, the cancer cells of each patient have different tumor antigens. Therefore, only personalized treatment approaches have the potential to have a durable effect.
The investigational therapy with autologous TIL is often described as a potential durable treatment for solid cancer tumors, representing ~90% of all cancer incidence. By targeting frequently occurring cancer types (breast and prostate cancer), Curacell strives to make significant impact for oncology patients worldwide.
Management
Medical Advisor